CATO News

Lidocaine Impurity Profile: Genotoxic Aniline Impurity and NDSRI Risk Under Control

CATO Research Chemicals Celebrates Topping-Out of New Global Headquarters

On June 30, CATO Research Chemicals topped out the primary structure of its new global headquarters in Guangzhou — a ~30,466 m² campus combining R&D, testing, and client-facing space. The milestone marks a key step in CATO's transformation from a reference standards company into a broader chemical enterprise, with the new campus set to support two core business lines: pharmacopeial reference standards and new functional materials.

Join us at CPHI China 2026 !

I am penning this letter to extend a cordial invitation for you to visit our booth E2B47 at the forthcoming CPHI China 2026 in Shanghai. As a preeminent platform within the pharmaceutical industry, CPHI offers an unparalleled opportunity for us to reconnect with esteemed partners and delve into novel prospects in drug development and quality control.

CATO CoA Upgrade：Professional Information at a Glance

CATO has upgraded the template for our Certificate of Analysis (CoA). The new certificate is now officially in use.

CATO Contributes to the Release of National Standard for Determining Isotopic Abundance in Deuterated Reagents

April 25, 2025 – Guangzhou, China — The State Administration for Market Regulation (SAMR) and the Standardization Administration of China (SAC) have officially released the national standard GB/T 45548-2025 Determination of Isotopic Abundance in Deuterated Reagents—Nuclear Magnetic Resonance (NMR) Spectroscopy.

CATO’s New Cosmetic Active Ingredient Series

As skincare formulation becomes more sophisticated, functional active ingredients are now central to product innovation and differentiation. For too long, the high-end cosmetic actives market has been dominated by a handful of global suppliers—resulting in high costs, long lead times, and limited sourcing flexibility for brands worldwide. To meet the growing demand for reliable, high-performance ingredients, CATO introduces its new Cosmetic Active Ingredient Series, featuring a diverse portfolio covering:

Notice on Packaging Change of CATO Products

Announcement on the Packaging Upgrade of CATO Reference Standards

REACH Annex XVII Adds New Restrictions on DMAC and NEP

On June 3, 2025, the European Union officially published Commission Regulation (EU) 2025/1090 in its Official Journal, introducing significant amendments to REACH Regulation Annex XVII by adding Articles 80 and 81. Two important industrial solvents—N,N-dimethylacetamide (DMAC) and 1-ethylpyrrolidin-2-one (NEP)—have been formally included in the restricted substances list.

CATO's Azithromycin-D5: Powering Precision Analytics

Azithromycin-D5 is synthesized by selectively replacing five specific hydrogen atoms in the azithromycin molecular structure with deuterium. It retains identical chemical properties while exhibiting distinct mass spectrometric characteristics.

Recommended Major Nitrosamine Impurities : N-Nitroso Finerenone

In recent years, drug safety issues have received significant attention. Among these, nitrosamine impurities have become a "Sword of Damocles" hanging over pharmaceutical companies. On March 28, 2025, the FDA updated its "Nitrosamine Impurities Acceptable Intake Limits" database. This update primarily added and adjusted acceptable intake limits for multiple nitrosamine impurities and expanded the substance categories determined by the prediction-based carcinogenic potency classification approach (CPCA), further strengthening drug safety regulations.